Turnstone Biologics Corp. (TSBX)
NASDAQ: TSBX · Real-Time Price · USD
0.4100
-0.0010 (-0.24%)
Mar 31, 2025, 10:46 AM EDT - Market open

Turnstone Biologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-19.3173.3101.29
Revenue Growth (YoY)
--73.66%-27.64%-
Cost of Revenue
-60.3879.6853.08
Gross Profit
--41.08-6.3848.21
Selling, General & Admin
16.3917.8518.2213.55
Research & Development
56.1---
Operating Expenses
72.4917.8518.2213.55
Operating Income
-72.49-58.92-24.6134.66
Other Non Operating Income (Expenses)
1.693.550.930.71
EBT Excluding Unusual Items
-70.8-55.38-23.6735.37
Other Unusual Items
--0.11-7.02-1.67
Pretax Income
-70.8-55.49-30.6933.7
Income Tax Expense
0.04-0.290.140.43
Net Income
-70.84-55.2-30.8333.27
Preferred Dividends & Other Adjustments
-0.040.1929.79
Net Income to Common
-70.84-55.24-31.023.48
Shares Outstanding (Basic)
231222
Shares Outstanding (Diluted)
231223
Shares Change (YoY)
99.23%365.39%-7.96%-
EPS (Basic)
-3.07-4.78-12.491.62
EPS (Diluted)
-3.07-4.78-12.491.28
Free Cash Flow
--67.4-76.23-49.04
Free Cash Flow Per Share
--5.83-30.68-18.16
Gross Margin
--212.76%-8.71%47.59%
Operating Margin
--305.21%-33.57%34.22%
Profit Margin
--286.12%-42.33%3.44%
Free Cash Flow Margin
--349.12%-104.00%-48.41%
EBITDA
-70.5-56.13-20.7136.05
EBITDA Margin
--290.71%-28.25%35.59%
D&A For EBITDA
22.83.91.39
EBIT
-72.49-58.92-24.6134.66
EBIT Margin
---33.57%34.22%
Effective Tax Rate
---1.28%
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q